I think it's important to recognize that these notions of pragmatic trials, or what are called designed delays, are typically applied in cases when we actually don't know if the new drug is in fact superior or if the new drug will cause more harm than good.
They're also designed in such a way that is referred to as a designed delay, and all populations who would be eligible for the treatment will eventually get it. It's just--